2-氨基-3-(4-甲烷磺酰氨基苯基)丙酸 | 266999-21-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-3-(4-甲烷磺酰氨基苯基)丙酸
• 中文别名: N~3~-[(2E)-1-甲基吡咯烷-2-亚基]吡啶-2,3-二胺；4-甲磺酰氨基-L-苯丙氨酸
• 英文名称: L-4-[(Methylsulfonyl)amino]phenylalanine
• 英文别名: (2S)-2-amino-3-[4-(methanesulfonamido)phenyl]propanoic acid
• CAS: 266999-21-7
• 化学式: C₁₀H₁₄N₂O₄S
• 分子量: 258.3
• InChiKey: JCDAIQZEQLVVRT-VIFPVBQESA-N

物化性质

• 沸点：
  458.4±55.0 °C(Predicted)
• 密度：
  1.451±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• 3-phenylpropionic acid derivatives
  申请人：Majka Zbigniew

  公开号：US20060160870A1

  公开（公告）日：2006-07-20

  The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R 1 to R 8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

  该发明涉及新化合物，化学式(I)中的3-苯丙酸衍生物，其中W代表COOH基团或其生物同位素，或—COO—C1-C4-烷基基团；Y代表NH、N—C1-C10-烷基、O或S；X代表O、S、NH、N—C1-C10-烷基、N-芳基、NSO2—C1-C10-烷基、N—SO2-芳基或N—SO2-杂芳基；R1至R8各自独立地代表氢原子或描述中定义的取代基；A如描述中所定义；n代表从0到4的整数（包括0和4）；以及其药学上可接受的盐。这些化合物是PPAR-γ受体的配体，可用作药物。
• 3-Phenylpropionic acid derivatives
  申请人：Majka Zbigniew

  公开号：US20060160868A1

  公开（公告）日：2006-07-20

  The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; Z represents NH, N—C 1 -C 10 -alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R 1 , to R 6 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

  该发明涉及新化合物，为公式I的3-苯基丙酸衍生物，其中W代表COOH基团或其生物异构体，或-COO-C1-C4-烷基基团；Y代表NH，N-C1-C10-烷基，O或S；Z代表NH，N-C1-C10-烷基，N-芳基，N-杂环芳基，S或O；X代表O，S，NH，N-C1-C10-烷基，N-芳基，NSO2-C1-C10-烷基，N-SO2-芳基或N-SO2-杂环芳基；R1至R6各自独立地代表氢原子或描述中定义的取代基；A如描述中所定义；n表示0至4的整数，包括0和4；以及其药学上可接受的盐。这些化合物是PPAR-gamma受体的配体，可用作药物。
• NEW 3-PHENYLPROPIONIC ACID DERIVATIVES
  申请人：Majka Zbigniew

  公开号：US20070219259A1

  公开（公告）日：2007-09-20

  The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO-C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; Z represents NH, N—C 1 -C 10 -alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R, to R 8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

  本发明涉及新的化合物，是式I的3-苯基丙酸衍生物，其中W代表COOH基团或其生物异构体，或-COO-C1-C4-烷基基团；Y代表NH，N-C1-C10-烷基，O或S；Z代表NH，N-C1-C10-烷基，N-芳基，N-杂环芳基，S或O；X代表O，S，NH，N-C1-C10-烷基，N-芳基，NSO2-C1-C10-烷基，N-SO2-芳基或N-SO2-杂环芳基；R到R8独立地代表氢原子或在说明中定义的取代基；A如说明中所定义；n表示0到4之间的整数，包括0和4；以及其药学上可接受的盐。这些化合物是PPAR-gamma受体的配体，可用作药物。
• New 3-phenylpropionic acid derivatives
  申请人：Majka Zbigniew

  公开号：US20070088061A1

  公开（公告）日：2007-04-19

  The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; Z represents NH, N—C 1 -C 10 -alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R 1 to R 8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

  该发明涉及一种新化合物，为公式I的3-苯基丙酸衍生物，其中W代表COOH基团或其生物异构体，或-COO-C1-C4-烷基基团；Y代表NH、N-C1-C10-烷基、O或S；Z代表NH、N-C1-C10-烷基、N-芳基、N-杂环芳基、S或O；X代表O、S、NH、N-C1-C10-烷基、N-芳基、NSO2-C1-C10-烷基、N-SO2-芳基或N-SO2-杂环芳基；R1到R8各自独立地代表氢原子或描述中定义的取代基；A如描述中所定义；n代表0到4的整数，包括0和4；以及其药学上可接受的盐。这些化合物是PPAR-gamma受体的配体，可用作药物。
• HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS
  申请人：Haque Shamsul Tasir

  公开号：US20070238669A1

  公开（公告）日：2007-10-11

  The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified compounds that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The compounds of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

  本发明提供了新型人类胰高血糖素样肽-1（GLP-1）受体调节剂，其生物活性类似或优于天然GLP-1肽，因此可用于治疗或预防与GLP活性相关的疾病或障碍。此外，本发明提供了新的化学修饰化合物，不仅可以刺激2型糖尿病患者的胰岛素分泌，还可以产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶水解的稳定性增加，使它们成为口服或静脉注射理想的治疗候选药物。本发明的化合物在糖尿病疗效模型中表现出理想的药代动力学特性和理想的效力。